Infectious crystalline keratopathy caused by Serratia marcescens.
OBJECTIVE
To report the case of a 70-year-old woman with Serratia infectious crystalline keratopathy.


METHODS
Case report.


RESULTS
This is a report of a 70-year-old woman with a history of chronic open-angle glaucoma and trachoma with lagophthalmos, entropion, and trichiasis in both eyes who developed crystalline keratopathy after penetrating keratoplasty and cataract extraction in the right eye followed up with treatment with long-term topical steroids. Ten months after the initial penetrating keratoplasty and cataract extraction, the patient had decreased visual acuity, intense pain, and tearing in the right eye. Corneal cultures showed Serratia marcescens. Topical steroids were discontinued, and treatment with tobramycin and vancomycin ophthalmic solution every hour was initiated. Despite 1 week of aggressive therapy, there was an increase in corneal infiltrate, epithelial defects, and melting, which eventually involved the peripheral recipient cornea. Therapeutic penetrating keratoplasty, debridement of the peripheral cornea, and amniotic membrane transplantation were performed. Antibiotic agents were used postoperatively. There has been no evidence of recurrent infection. The best-corrected visual acuity improved to 6/15 at the 6-month follow-up period after the second intervention.


CONCLUSIONS
S. marcescens may cause infectious crystalline keratopathy after penetrating keratoplasty in patients treated with long-term topical steroids. Therapeutic penetrating keratoplasty, surgical debridement, and amniotic membrane transplantation may be necessary when the clinical response to intensive medical treatment is inadequate.
Chen
Ching-Long
CL
Department of Ophthalmology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China.
Tai
Ming-Cheng
MC
Chen
Jiann-Torng
JT
Chen
Chiao-Hong
CH
Lu
Da-Wen
DW
D000368:Aged; D000650:Amnion / Q000637:transplantation; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003315:Cornea / Q000382:microbiology*; D003316:Corneal Diseases / Q000175:diagnosis / Q000382:microbiology* / Q000628:therapy; D003646:Debridement; D004359:Drug Therapy, Combination; D015818:Eye Infections, Bacterial / Q000175:diagnosis / Q000382:microbiology* / Q000628:therapy; D005260:Female; D005469:Fluorometholone / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D015948:Keratoplasty, Penetrating; D016868:Serratia Infections / Q000175:diagnosis / Q000382:microbiology* / Q000628:therapy; D012706:Serratia marcescens / Q000302:isolation & purification*; D014031:Tobramycin / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D005938:Glucocorticoids; D005469:Fluorometholone; D014031:Tobramycin